Adicet Bio, Inc. Restructuring and Related Cost, Number of Positions Eliminated
Adicet Bio, Inc. (ACET) reported Restructuring and Related Cost, Number of Positions Eliminated of 0 Employee for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-07-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2020-07-30
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 1 month | Restructuring and Related Cost, Number of Positions Eliminated 6 month | Restructuring and Related Cost, Number of Positions Eliminated 12 month |
|---|---|---|---|
| 2020-06-30 | 0.00 Employee 10-Q · filed 2020-07-30 | ||
| 2020-01-31 | 2.00 Employee 10-Q · filed 2020-07-30 | ||
| 2019-12-31 | 8.00 Employee 10-Q · filed 2020-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |